% of Cases treated with Teletherapy
Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
---|---|---|---|---|---|---|
All invasive xnmsc | 18.1% | 18.4% | 18.2% | 14.9% | 21.5% | 19.1% |
All xnmsc 0-24 | 11.9% | 11.7% | 12.0% | 10.8% | 14.8% | 9.3% |
All xnmsc 25-59 | 21.9% | 23.3% | 21.8% | 20.4% | 26.0% | 25.1% |
All xnmsc 60-79 | 19.9% | 20.1% | 20.1% | 15.7% | 24.0% | 20.5% |
All xnmsc 80+ | 10.3% | 9.7% | 10.5% | 7.5% | 10.2% | 10.7% |
Haematology | 8.8% | 7.4% | 9.0% | 8.2% | 4.5% | 7.9% |
Head and Neck | 57.3% | 55.1% | 59.5% | 32.8% | 61.8% | 66.5% |
Lower GI | 12.5% | 12.6% | 12.6% | 10.2% | 14.1% | 13.5% |
Upper GI | 18.2% | 17.1% | 18.9% | 9.9% | 15.4% | 24.3% |
HPB | 2.1% | 2.2% | 2.2% | 1.2% | 2.2% | 3.1% |
Trachea, Bronchus & Lung | 25.0% | 25.6% | 25.0% | 24.2% | 29.0% | 24.3% |
Melanoma of skin | 1.1% | 0.8% | 1.2% | 0.3% | 0.9% | 0.9% |
Breast | 32.4% | 33.9% | 32.2% | 32.1% | 39.6% | 31.8% |
Cervix | 40.7% | 41.2% | 40.3% | 42.1% | 35.6% | 46.9% |
Other Female Genitals | 9.3% | 11.6% | 8.9% | 7.3% | 14.0% | 16.0% |
Prostate | 16.2% | 14.4% | 17.2% | 4.1% | 22.5% | 13.9% |
Kidney | 5.6% | 6.9% | 5.4% | 6.6% | 7.8% | 8.0% |
Bladder | 18.3% | 18.6% | 18.4% | 16.1% | 18.3% | 21.7% |
Brain and CNS | 43.8% | 41.1% | 44.8% | 30.9% | 42.3% | 46.6% |
Thyroid & other endocrine glands | 7.3% | 13.2% | 6.5% | 1.8% | 26.3% | 18.2% |
CUP | 9.0% | 10.0% | 9.0% | 7.5% | 14.4% | 9.1% |
Other invasive cancer | 10.8% | 11.7% | 10.9% | 7.8% | 17.0% | 10.9% |
Breast in situ | 26.4% | 30.2% | 25.7% | 31.6% | 43.8% | 19.7% |
Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.3% | 0.0% |
Other tumours | 0.8% | 0.8% | 0.9% | 0.1% | 1.5% | 0.6% |
Non-Melanoma Skin Cancer | 1.6% | 1.3% | 1.7% | 0.6% | 1.5% | 1.4% |